Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00

Kura Oncology (NASDAQ:KURA) had its target price reduced by Mizuho from $30.00 to $25.00 in a report issued on Tuesday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

A number of other research analysts have also recently issued reports on the company. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Wedbush dropped their target price on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Leerink Partners set a $20.00 price target on Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Wall Street Zen cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.86.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $8.36 on Tuesday. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $12.49. The stock has a market capitalization of $738.44 million, a price-to-earnings ratio of -2.63 and a beta of 0.22. The company has a fifty day moving average of $8.44 and a 200-day moving average of $9.48. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.06.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). The business had revenue of $17.34 million during the quarter, compared to analysts’ expectations of $34.71 million. Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%. Equities research analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Insider Activity

In other news, SVP Thomas James Doyle sold 7,142 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the transaction, the senior vice president directly owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Teresa Brophy Bair sold 11,208 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $94,819.68. Following the sale, the insider owned 226,931 shares of the company’s stock, valued at approximately $1,919,836.26. This represents a 4.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 36,068 shares of company stock worth $305,135 over the last ninety days. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the business. IFP Advisors Inc raised its holdings in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after acquiring an additional 3,072 shares in the last quarter. Allworth Financial LP boosted its holdings in Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after purchasing an additional 3,769 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.